BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cohera Medical, Inc. Brings Hope to Easier Healing Following Mastectomy Procedures With Innovative Surgical Adhesive


5/14/2013 9:40:24 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PITTSBURGH, May 14, 2013 /PRNewswire/ -- Cohera Medical, Inc.® (www.coheramedical.com), a leading innovator and developer of absorbable surgical adhesives and sealants, announced it has completed a series of mastectomy procedures in Munich and Berlin, Germany using TissuGlu® Surgical Adhesive without drain placement. With this innovative adhesive technology, surgeons were able to eliminate the need for closed-suction drains on breast cancer patients undergoing mastectomy procedures.

"Surgeons have recognized the limitations in using closed suction drains in mastectomy procedures for some time," says Prof. Blohmer of the Sankt Gertrauden-Krankenhaus, Berlin. "German plastic surgeons have already demonstrated the use of TissuGlu to eliminate drains in other reconstructive methods. Using this surgical adhesive in no-drain mastectomy procedures will increase patient comfort and ease the healing process."

According to the Susan G. Komen Foundation there will be more than 232,000 new cases of invasive breast cancer in the U.S. this year. Most people with invasive breast cancer undergo a mastectomy to remove their breast. Surgical drains are used in this procedure to help the healing process. The surgical drains must be attended to properly and can become blocked by fluid at the surgical site. Left untreated, this accumulation may cause infection and/or delayed healing.

"TissuGlu has the potential to transform the healing process following a mastectomy procedure," said Patrick Daly, president and CEO of Cohera Medical. "We are excited to use this technology in no-drain mastectomies, providing breast cancer patients with a more natural healing process that has a reduced risk for complications."

Cohera Medical received CE Marking approval for TissuGlu and began selling product to hospitals and surgeons in Germany in September 2011. An earlier no-drain study of 30 patients was successfully completed in Germany in July 2012. In the U.S., Cohera recently completed enrollment of a clinical trial for TissuGlu. TissuGlu has been used successfully in over 600 various surgical procedures by leading surgeons.

About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.

SOURCE Cohera Medical, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES